EUCTR2005-005463-28-LT进行中（未招募）不适用
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF 2 FIXED DOSES (50 mg, 100 mg) OF DESVENLAFAXINE SUSTAINED-RELEASE TABLETS IN ADULT OUTPATIENTS WITH MAJOR DEPRESSIVE DISORDER
Wyeth Pharmaceuticals France, Wyeth Research Division0 个研究点目标入组 480 人开始时间: 2006年2月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 480
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Outpatient men and women at least 18 years of age.
- •2. Except for women of non-child bearing potential, sexually active individuals participating in the study must agree to use a medically acceptable form of contraception during the study and for at least 15 days after the last dose of test article. Medically acceptable forms of contraception include oral contraceptives, injectable or implantable methods, intrauterine devices, or properly used double-barrier contraception, eg, condom plus diaphragm. It is important that subjects not become pregnant or impregnate others while they are in this study.
- •3. Have a primary diagnosis of MDD based on the criteria in the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV), single or recurrent episode, without psychotic features. If other allowable psychiatric diagnoses (see exclusion criterion 5) are present, MDD must be the predominant psychiatric disorder present.
- •4. Have depressive symptoms for at least 30 days before the screening visit.
- •5. Have a HAM-D17 total score =20 at the screening and baseline (study day –1) visits.
- •6. Have a score =2 on item 1 (depressed mood) of the HAM-D17 at the screening and baseline (study day –1) visits.
- •7. Have a score =4 on the Clinical Global Impressions Scale-Severity (CGI-S) at the screening and baseline (study day –1) visits.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Treatment with DVS SR at any time in the past.
- •2. Known hypersensitivity to venlafaxine (immediate release [IR] or extended release [ER]).
- •3. Significant risk of suicide based on clinical judgment, including common suicidal thoughts and suicide having been considered as a possible solution even without specific plans or intent.
- •4. Women who are pregnant, breastfeeding, or plan to become pregnant during the study (for women of childbearing potential). A woman of childbearing potential is one who is biologically capable of becoming pregnant. This includes women who are using contraceptives or whose sexual partners are either sterile or using contraceptives.
- •5. a) Current (within 12 months before baseline) psychoactive substance abuse or dependence (including alcohol), manic episode, posttraumatic stress disorder, obsessive-compulsive disorder, or a lifetime diagnosis of bipolar or psychotic disorder as assessed by the modified Mini International Neuropsychiatric Interview (MINI) and confirmed by the investigator.
- •b) current (within 12 months before baseline) generalized anxiety disorder, panic disorder, or social anxiety disorder as assessed by the modified MINI and considered by the investigator to be primary (causing a higher degree of distress or impairment than MDD); c) Presence (within 12 months before baseline) of a clinically important personality disorder (such as antisocial, schizotypal, histrionic, borderline, narcissistic) as assessed during the psychiatric evaluations.
- •6. A Covi Anxiety Scale total score greater than the Raskin Depression Scale total score at the screening or baseline (study day –1) visits.
- •7. A Covi Anxiety Scale score greater than 3 on any single item or a total score greater than 9 at the screening or baseline (study day –1) visits.
- •8. Depression associated with the presence of an organic mental disorder due to a general medical condition or a neurologic disorder.
- •9. History of seizure disorder other than a single childhood febrile seizure.
- •10. Any unstable hepatic, renal, pulmonary, cardiovascular (including uncontrolled hypertension), ophthalmologic, neurologic, or any other medical condition that might confound the study or put the subject at greater risk during study participation.
- •11. History or current evidence of gastrointestinal disease known to interfere with the absorption or excretion of drugs or a history of surgery known to interfere with the absorption or excretion of drugs.
- •12. History of neoplastic disorder (within 2 years), with the exception of basal cell or squamous cell carcinoma of the skin.
- •13. Known presence of raised intraocular pressure or history of narrow-angle glaucoma.
- •14. Major acute illness within 90 days before the screening visit.
- •15. Myocardial infarction within 180 days before the screening visit.
- •16. Clinically important abnormalities, as determined by the investigator, on screening physical examination, electrocardiogram (ECG), laboratory tests, or urine drug screen (UDS). The investigator and medical monitor will evaluate a positive UDS as to the potential impact and continued participation of the subject in the study.
- •17. Use of prohibited treatments. Refer to sections 13.1 and 13.2 and Table 13.1.1 (Prohibited Treatment, Permitted Treatment, and Table of Prohibited Treatments, respectively) for treatments and associated time frames.
研究者
相似试验
进行中（未招募）
1 期
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF A NOVEL CCR5 ANTAGONIST, UK-427,857, IN COMBINATION WITH OPTIMIZED BACKGROUND THERAPY VERSUS OPTIMIZED BACKGROUND THERAPY ALONE FOR THE TREATMENT OF ANTIRETROVIRAL EXPERIENCED, NON CCR5-TROPIC HIV-1 INFECTED SUBJECTSK-427,857 is an antagonist of the human chemokine receptor, and is intended to help prevent the development and progression of AIDS in individuals HIV-1 positive.EUCTR2004-001779-20-GBPfizer Limited186
进行中（未招募）
1 期
A Study of RO6885247 in Adult and Pediatric Patients with Spinal Muscular Atrophy (MOONFISH)MedDRA version: 18.0Level: PTClassification code 10041582Term: Spinal muscular atrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersSpinal Muscular AtrophyEUCTR2014-002246-41-ESRoche Farma S.A., en nombre de F. Hoffmann-La Roche Ltd.64
进行中（未招募）
1 期
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY EVALUATING THE EFFICACY AND SAFETY OF DAXDILIMAB IN ADULT PARTICIPANTS WITH ACTIVE PROLIFERATIVE LUPUS NEPHRITISACTIVE PROLIFERATIVE LUPUS NEPHRITISMedDRA version: 21.1Level: PTClassification code 10025140Term: Lupus nephritisSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2022-001377-31-ESHorizon Therapeutics Ireland DAC210
进行中（未招募）
1 期
PROOF OF CONCEPT STUDY TO EVALUATE THE EFFECTS OF TASIMELTEON AND MATCHING PLACEBO IN TRAVELERS WITH JET LAG DISORDERJet Lag Disorder (JLD)MedDRA version: 20.0 Level: PT Classification code 10040984 Term: Sleep disorder System Organ Class: 10037175 - Psychiatric disordersEUCTR2016-002213-21-GBVanda Pharmaceuticals Inc90
进行中（未招募）
不适用
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF A COMBINATION OF LEVONORGESTREL AND ETHINYL ESTRADIOL IN A CONTINUOUS DAILY REGIMEN IN SUBJECTS WITH PREMENSTRUAL DYSPHORIC DISORDERPremenstrual dysphoric disorder (PMDD) affects 3% to 5% of menstruating women. PMDD is defined by markedly depressed mood, anxiety, and/or affective lability during the last week of the late luteal phase with absence of these symptoms in the postmenses week. These symptoms markedly interfere with work or school or with usual social activities and relationships with others. Suppression of ovarian cyclicity is known to alleviate symptoms of PMDD.EUCTR2004-005173-27-DEWyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development90